Bright Minds Biosciences ... (DRUG)
NASDAQ: DRUG
· Real-Time Price · USD
24.21
-0.57 (-2.30%)
At close: Jun 27, 2025, 12:35 PM
-2.30% (1D)
| Bid | 24.17 |
| Market Cap | 171.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.06M |
| EPS (ttm) | -0.14 |
| PE Ratio (ttm) | -172.92 |
| Forward PE | -6.67 |
| Analyst | Buy |
| Ask | 24.73 |
| Volume | 18,297 |
| Avg. Volume (20D) | 27,482 |
| Open | 24.92 |
| Previous Close | 24.78 |
| Day's Range | 24.17 - 25.61 |
| 52-Week Range | 0.93 - 79.02 |
| Beta | 0.45 |
About DRUG
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DRUG
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DRUG stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 days ago
+3.36%
Shares of psychedelic companies are trading higher...
Unlock content with
Pro Subscription
7 months ago
-1.24%
Bright Minds Biosciences shares are trading higher after Baird initiated coverage on the stock with an Outperform rating and announced a price target of $75.
2 months ago · seekingalpha.com
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025We are initiating coverage of Bright Minds Biosciences with a Buy rating, as we believe the stock is undervalued. We see a key catalyst in the Phase 2 data readout for BMB-101, which is expected in Q2...